Aptuit buys Kuecept

Aptuit LLC, which is backed by Welsh, Carson, and Anderson & Stowe, has acquired Kuecept Ltd. Financial terms weren’t announced. London-based Kuecept provides technical expertise in CRO services supporting preclinical drug development.


GREENWICH, Connecticut, May 10, 2016 /PRNewswire/ —

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototypingand formulation development services 

Aptuit, LLC today announced that it has acquired Kuecept Ltd to meet strong customer demand for specialist drug pre-formulation, formulation prototyping and formulation development services.

(Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO )

Located in London, UK, Kuecept offers industry leading technical expertise in CRO services supporting preclinical drug development. Kuecept provides pre-formulation testing, preclinical dose-vehicle screening and formulation development.  These are complemented by a comprehensive range of enabling drug-delivery technologies. Kuecept has deep experience in respiratory, parenteral and oral formulation development for insoluble compounds. Formulation rescue consultancy helps companies move APIs through IND/CTA enabling safety assessment.

Aptuit CEO Dr. Jonathan Goldman stated, “We offer solutions in the fields of integrated drug discovery, CMC and preclinical biosciences. The acquisition of Kuecept enhances our scientific expertise and capabilities in the pre-formulation development space. The addition allows us to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory based Drug Product Development”.  Dr. Goldman added that, “Kuecept scientists are skilled in utilizing small milligram quantities of API in the critical de-risking phase of late stage discovery. Technologies such as hot melt extrusion, spray drying, wet and dry micronization and cutting edge microsphere chemistry are all routinely performed on very small amounts of API to develop robust and practical formulations. Kuecept’s knowledge also further enhances our unique fully integrated candidate to IND/CTA solution (INDiGO). We expect our customers to benefit from improved solubility solutions, reduced drug attrition and associated reductions in time and development costs.”

Dr. Mark Saunders, CEO and founder of Kuecept added, “Since our inception in 2007, we have focused our efforts on the provision of flexible, cost effective and responsive preclinical R&D services. Through this acquisition, our customers can now combine our capabilities with Aptuit’s full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture. Kuecept and Aptuit share a common culture and commitment to scientific excellence, making this a very good fit.”

About Aptuit, LLC

Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world’s leading private equity investors.

For more information, please visit http://www.aptuit.com